Remdesivir has been issued an Emergency Use Authorization by the United States Food and Drug Administration to treat hospitalised coronavirus patients A US pharmaceutical giant has applied to India's drug regulator seeking marketing authorisation for its anti-viral drug remdesivir, which is being touted as a potential treatment for COVID-19.
Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said. "The company has applied seeking marketing authorisation for its anti-viral drug remdesivir to India's Central Drugs Standard Control Organisation (CDSCO).